These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 27925198)
21. HER2 in stemness and epithelial-mesenchymal plasticity of breast cancer. Voutsadakis IA Clin Transl Oncol; 2019 May; 21(5):539-555. PubMed ID: 30306401 [TBL] [Abstract][Full Text] [Related]
22. Implications of stemness-related signaling pathways in breast cancer response to therapy. Angeloni V; Tiberio P; Appierto V; Daidone MG Semin Cancer Biol; 2015 Apr; 31():43-51. PubMed ID: 25153354 [TBL] [Abstract][Full Text] [Related]
23. Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells. Huang WC; Hung CM; Wei CT; Chen TM; Chien PH; Pan HL; Lin YM; Chen YJ Oncotarget; 2016 Sep; 7(38):62352-62363. PubMed ID: 27694691 [TBL] [Abstract][Full Text] [Related]
24. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling. Pandian V; Ramraj S; Khan FH; Azim T; Aravindan N Stem Cell Res Ther; 2015 Feb; 6(1):2. PubMed ID: 25888913 [TBL] [Abstract][Full Text] [Related]
25. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer. Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735 [TBL] [Abstract][Full Text] [Related]
26. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243 [TBL] [Abstract][Full Text] [Related]
27. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. Karthik GM; Ma R; Lövrot J; Kis LL; Lindh C; Blomquist L; Fredriksson I; Bergh J; Hartman J Cancer Lett; 2015 Oct; 367(1):76-87. PubMed ID: 26208432 [TBL] [Abstract][Full Text] [Related]
28. MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Roscigno G; Puoti I; Giordano I; Donnarumma E; Russo V; Affinito A; Adamo A; Quintavalle C; Todaro M; Vivanco MD; Condorelli G Oncotarget; 2017 Mar; 8(12):19507-19521. PubMed ID: 28061479 [TBL] [Abstract][Full Text] [Related]
29. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells. Ma X; Wang B; Wang X; Luo Y; Fan W PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047 [TBL] [Abstract][Full Text] [Related]
30. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Ma L; Lai D; Liu T; Cheng W; Guo L Acta Biochim Biophys Sin (Shanghai); 2010 Sep; 42(9):593-602. PubMed ID: 20705681 [TBL] [Abstract][Full Text] [Related]
31. Lung cancer stem cells: The root of resistance. MacDonagh L; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP Cancer Lett; 2016 Mar; 372(2):147-56. PubMed ID: 26797015 [TBL] [Abstract][Full Text] [Related]
32. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells. Alberti L; Losi L; Leyvraz S; Benhattar J PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells. Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893 [TBL] [Abstract][Full Text] [Related]
34. Induction of HEXIM1 activities by HMBA derivative 4a1: Functional consequences and mechanism. Ketchart W; Yeh IJ; Zhou H; Thiagarajan PS; Lathia J; Reizes O; Exner A; Su B; Montano MM Cancer Lett; 2016 Aug; 379(1):60-9. PubMed ID: 27238569 [TBL] [Abstract][Full Text] [Related]
35. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507 [TBL] [Abstract][Full Text] [Related]
36. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway. Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383 [TBL] [Abstract][Full Text] [Related]
37. Anti-Tumor Effects of Cardiac Glycosides on Human Lung Cancer Cells and Lung Tumorspheres. Kaushik V; Yakisich JS; Azad N; Kulkarni Y; Venkatadri R; Wright C; Rojanasakul Y; Iyer AKV J Cell Physiol; 2017 Sep; 232(9):2497-2507. PubMed ID: 27662422 [TBL] [Abstract][Full Text] [Related]
38. A potent indolylquinoline alleviates growth of human lung cancer cell tumorspheres. Ni YL; Hsieh CH; Kim SH; Wang JP; Su CL; Yao CF; Fang K Apoptosis; 2017 Oct; 22(10):1235-1245. PubMed ID: 28741092 [TBL] [Abstract][Full Text] [Related]
39. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579 [TBL] [Abstract][Full Text] [Related]
40. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells. Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]